Dianthus Therapeutics, Inc. $DNTH Shares Bought by Fairmount Funds Management LLC

Fairmount Funds Management LLC grew its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 22.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,307,191 shares of the company’s stock after purchasing an additional 600,000 shares during the period. Dianthus Therapeutics makes up about 11.7% of Fairmount Funds Management LLC’s investment portfolio, making the stock its largest position. Fairmount Funds Management LLC owned approximately 0.08% of Dianthus Therapeutics worth $130,138,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in DNTH. Brevan Howard Capital Management LP purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at $469,000. Bank of America Corp DE increased its stake in Dianthus Therapeutics by 9.0% during the 3rd quarter. Bank of America Corp DE now owns 180,025 shares of the company’s stock worth $7,084,000 after buying an additional 14,900 shares during the period. Boothbay Fund Management LLC purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth $5,468,000. Braidwell LP acquired a new position in Dianthus Therapeutics in the 3rd quarter worth $32,859,000. Finally, Ameriprise Financial Inc. lifted its holdings in Dianthus Therapeutics by 84.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 103,755 shares of the company’s stock worth $4,083,000 after buying an additional 47,494 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $77.86 on Monday. The firm has a fifty day moving average of $52.53 and a two-hundred day moving average of $42.82. The firm has a market cap of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DNTH. HC Wainwright upped their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Wedbush boosted their price target on Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Oppenheimer raised their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $115.33.

Insider Activity at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 200,430 shares of company stock valued at $16,332,702 over the last three months. 16.56% of the stock is owned by insiders.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.